Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
- 13 October 2016
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 19 (1) , 215-222
Abstract
Standard of care (SOC; combination of 5-10 mg/kg and an interval every 6-8 weeks) dosing of infliximab (IFX) is associated with significant loss of response. Dashboards using covariates that influence IFX pharmacokinetics (PK) may be a more precise way of optimizing anti-TNF dosing. We tested a prototype dashboard to compare forecasted dosing regimens with actual administered regimens and SOC. Fifty IBD patients completing IFX induction were monitored during maintenance (weeks 14-54). Clinical and laboratory data were collected at each infusion; serum was analyzed for IFX concentrations and anti-drug antibodies (ADA) at weeks 14 and 54 (Prometheus Labs, San Diego). Dosing was blinded to PK data. Dashboard-based assessments were conducted on de-identified clinical, laboratory, and PK data. Bayesian algorithms were used to forecast individualized troughs and determine optimal dosing to maintain target trough concentrations (3 μg/mL). Dashboard forecasted dosing post-week 14 was compared to actual administered dose and frequency and SOC. Using week 14 clinical data only, the dashboard recommended either a dose or an interval change (<0.5 mg/kg or <1 week difference) in 43/50 patients; only 44% recommended to have SOC dosing. When IFX14 concentration and ADA status were added to clinical data, dose and/or interval changes based on actual dosing were recommended in 48/50 (96%) patients; SOC dosing was recommended in only 11/50 (22%). Dashboard recommended SOC IFX dosing in a minority of patients. Dashboards will be an important tool to individualize IFX dosing to improve treatment durability.Keywords
This publication has 25 references indexed in Scilit:
- Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodiesThe Journal of Clinical Pharmacology, 2015
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trialGut, 2014
- Therapeutic drug monitoring in patients with inflammatory bowel diseaseWorld Journal of Gastroenterology, 2014
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be TransientAmerican Journal of Gastroenterology, 2013
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- The impact of biologics on health-related quality of life in patients with inflammatory bowel diseaseClinical and Experimental Gastroenterology, 2009
- Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2006
- Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s diseaseGastroenterology, 2005
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Individual adaptive dosing of topotecan in ovarian cancer.2002